PharmEasy to pick up 66.1% stake in Thyrocare for Rs 4,546 crore

Online medicine delivery firm PharmEasy on Friday announced that its parent API Holdings Ltd (API) will acquire 66.1 per cent stake in Thyrocare for Rs 4,546 crore from Dr A Velumani affiliates.

Thyrocare is the largest B2B player in the diagnostics space has a network of 3,330+ collection centres across in 2,000+ towns in India.

On the addition of Thyrocare into its portfolio, Mr Siddharth Shah, CEO, API Holdings said: “We are delighted to be partnering Thyrocare. We will provide world class customer experience in diagnostics, rivalling our pharmacy experience by leveraging technology, building on top of the massive scale & truly pan-India presenceof Thyrocare. It is our aim to deliver all outpatient healthcare products & services to every Indian within 24 hours.

Dr A Velumani will be separately acquiring a minority non-controlling stake, of less than 5 per cent in API as part of a series of equity investments by existing new investors of API.

“I am excited about this relationship, unique of its kind in Indian Healthcare Industry. The unique reach strength of Thyrocare in Diagnostics blended with young dynamic team of PharmEasy will bring in better healthcare solutions for common man nationwide,” said Dr A Velumani, Chairman & MD of Thyrocare.

The combined entity will have the ability to provide diagnostics pharmacy services to 100 million-plus Indians within 24 hours, the company said in a statement.

The landmark partnership will bring seamless, tech-enabled healthcare for consumers, doctors suppliers, it further said.

The transaction is subject to regulatory other applicable customary approvals.

Docon Technologies Pvt Ltd, a 100 per cent subsidiary of API, will be the acquirer shall make an open offer for an additional 26 per cent stake.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information commentary on developments that are of interest to you have wider political economic implications for the country the world. Your encouragement constant feedback on how to improve our offering have only made our resolve commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed updated with credible news, authoritative views incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better more relevant content. We believe in free, fair credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism subscribe to Business Standard.

Digital Editor

Source link